10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
Baricitinib works better than methotrexate for severe alopecia areata.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” 20 citations
,
February 2004 in “Clinical & Experimental Immunology” SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
6 citations
,
June 2008 in “Journal of the European Academy of Dermatology and Venereology” A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
13 citations
,
June 2010 in “Journal of dermatological treatment” Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
16 citations
,
April 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” A patient lost all their hair while on rheumatoid arthritis medication.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
38 citations
,
January 2009 in “Journal of Cutaneous Medicine and Surgery” A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.